← All trials
NCT04557306
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 12, 2020
- Primary completion
- Jan 7, 2022
- Completion date
- Feb 17, 2022
- First posted
- Sep 21, 2020
- Last posted
- Sep 22, 2020
- Enrollment
- 12
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- CHABiotech CO., LtdLead sponsor
- Cha Medical UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.